Morgan Stanley Orchard Therapeutics PLC Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.36 - $0.49 $2,184 - $2,973	-6,069 Reduced 2.04%	291,411 $107,000
Q3 2022 Nov 14, 2022	SELL	$0.45 - $0.69 $29,282 - $44,900	-65,073 Reduced 17.95%	297,480 $149,000
Q2 2022 Oct 27, 2022	BUY	$0.42 - $0.78 $24,403 - $45,320	58,103 Added 19.08%	362,553 $212,000
Q2 2022 Aug 15, 2022	BUY	$0.42 - $0.78 $24,403 - $45,320	58,103 Added 19.08%	362,553 $212,000
Q1 2022 Oct 27, 2022	SELL	$0.7 - $1.51 $40,672 - $87,735	-58,103 Reduced 16.03%	304,450 $217,000
Q1 2022 May 13, 2022	SELL	$0.7 - $1.51 $63,310 - $136,570	-90,444 Reduced 22.9%	304,450 $217,000
Q4 2021 Feb 14, 2022	BUY	$1.16 - $2.23 $285,471 - $548,794	246,096 Added 165.39%	394,894 $522,000
Q3 2021 Nov 15, 2021	BUY	$2.24 - $4.29 $333,307 - $638,343	148,798 New	148,798 $342,000

545K

Ticker ORTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,458,000
Description
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's d...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.